title: Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
abstract: The Fragmin and/or Early Revascularisation during Instability in Coronary Artery Disease (FRISC II) trial will, in a prospective multicenter factorially randomized study, compare the efficacy of 3 months continuation of subcutaneous treatment with the low-molecular-weight heparin dalteparin (Fragmin) with that of placebo and will also compare a direct invasive strategy with a stepwise selective approach with regard to the utilization of coronary angiography and revascularization in patients with unstable coronary artery disease. The primary endpoints are death or myocardial infarction after 3 and 6 months respectively. Secondary endpoints are the same events after 12-24 months and also cardiac symptoms, exercise capacity, and/or signs of myocardial ischemia, readmission, and costs. Analyses will also be made of subgroups based on inclusion diagnosis, initial elevation of biochemical markers of myocardial damage, elevation of fibrinogen or C-reactive protein, signs of ischemia in electrocardiography at rest or at continuous 24-hour ischemia monitoring, and left ventricular function at echocardiography. Altogether, 3,100 patients will be recruited in 65-70 Scandinavian centers. Completion of follow-up is anticipated in the second half of 1998. The FRISC II study will further elucidate new alternatives for antithrombotic, invasive, and individually tailored treatment of unstable coronary syndromes.
authors.affiliation: Department of Cardiology, University of Uppsala, Sweden.
authors.forename: L
authors.initials: L
authors.lastname: Wallentin
authors.forename: S
authors.initials: S
authors.lastname: Husted
authors.forename: F
authors.initials: F
authors.lastname: Kontny
authors.forename: E
authors.initials: E
authors.lastname: Swahn
mesh_terms: D000789:Angina, Unstable / Q000188:drug therapy; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000188:drug therapy* / Q000601:surgery; D017985:Dalteparin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D009204:Myocardial Revascularization; D016032:Randomized Controlled Trials as Topic; D015912:Thrombolytic Therapy
chemical_list: D000925:Anticoagulants; D017985:Dalteparin